



News Release

Source: Patheon Inc.

Website: www.patheon.com

Patheon Inc. Adds Capability to Conduct Cell Based Assays

RESEARCH TRIANGLE PARK, North Carolina, (May 19, 2009) – Patheon Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, is pleased to announce the introduction of cell based assay services to support biopharmaceutical product development.

The new services will strengthen Patheon's existing analytical capability in biopharmaceutical analysis. Cell based assays are a key technology used in determining the biological potency of biopharmaceuticals required for product licensing procedures. Biological potency analytics and the required supporting capabilities for tissue culture, such as assessment of cell viability and production of master and working cell banks, will take place at Patheon's Swindon, UK facility. This will enable all the analytical needs for biopharmaceutical product development to be completed in one location.

Wes Wheeler, President and CEO of Patheon Inc. stated, "Expanding the services provided through using cell based assays at our Swindon facility, is a testament to the commitment Patheon has to enhancing and growing the Pharmaceutical Development Services provided to our customers. This new capability allows us to better meet the needs of customers in the early stages of drug development."

The facility will be managed and supported by a team of scientists with approximately 18 years of combined experience in tissue culture and cell based assays. The facility will be fully available for use at the end of May.

ABOUT PATHEON

Patheon Inc. (TSX: PTI; www.patheon.com) is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to more than 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.

Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic™ programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable

API. Patheon's integrated network strives to ensure that customer products can be launched with confidence globally.

Caution Concerning Forward-Looking Statements

This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at www.patheon.com or on SEDAR at www.sedar.com.

Contacts:

Mr. Wes Wheeler
President & Chief Executive Officer
Tel: (919) 226-3200
Email: wes.wheeler@patheon.com

Mr. Norman Barras
Vice President, PDS Europe
Tel: +44(0)7725 423431
Email: norman.barras@patheon.com

Mr. Eric Evans
Chief Financial Officer
Tel: (919) 226-3200
Email: eric.evans@patheon.com